First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies

NCT04763083 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Lymphocytic Leukaemia
Small Lymphocytic Lymphoma
Mantle Cell Lymphoma
Follicular Lymphoma
Diffuse Large B Cell Lymphoma
Non-small Cell Lung Cancer (NSCLC)
Malignant Melanoma

Interventions

DRUG: NVG-111

Sponsor

NovalGen Ltd.